Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor

Background: Aberrant activation of RAS-RAF-MEK-ERK signaling pathway has been implicated in more than one-third of all malignancies. MEK inhibitors are promising therapeutic approaches to target this signaling pathway. Though four MEK inhibitors have been approved by FDA, these compounds possess eit...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yahong, Cheng, Ying, Huang, Gongchao, Xia, Xiangying, Wang, Xingkai, Tian, Hongqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557067/
https://www.ncbi.nlm.nih.gov/pubmed/37808191
http://dx.doi.org/10.3389/fphar.2023.1271268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557067/
https://www.ncbi.nlm.nih.gov/pubmed/37808191
http://dx.doi.org/10.3389/fphar.2023.1271268

Ejemplares similares